| Aug to Nov 2027Quarter disclosed | hz/su vaccine | GSK | Topline readout | Herpes Zoster | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2027Quarter disclosed | camlipixant (BLU-5937) | GSK | Topline readout | Refractory Chronic Cough | Scheduled | ClinicalTrials.gov |
| August 2027Month disclosed | hz/su vaccine | GSK | Primary completion | Herpes Zoster | Scheduled | ClinicalTrials.gov |
| August 2027Month disclosed | camlipixant (BLU-5937) | GSK | Primary completion | Refractory Chronic Cough | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | depemokimab (GSK3511294) | GSK | Topline readout | Hypereosinophilic Syndrome | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | Jemperli (dostarlimab) | GSK | Topline readout | Neoplasms, Rectal | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | VH4524184 | GSK | Topline readout | HIV Infections | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | gsk3772701 600 mg (GSK3772701) | GSK | Topline readout | Malaria, Falciparum | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | gsk3772701 600 mg (GSK3772701) | GSK | Primary completion | Malaria, Falciparum | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | Jemperli (dostarlimab) | GSK | Primary completion | Neoplasms, Rectal | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | VH4524184 | GSK | Primary completion | HIV Infections | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | depemokimab (GSK3511294) | GSK | Primary completion | Hypereosinophilic Syndrome | Scheduled | ClinicalTrials.gov |
| Nov 2027 to Feb 2028Quarter disclosed | GSK4532990 | GSK | Topline readout | Liver Diseases, Alcoholic | Scheduled | ClinicalTrials.gov |
| Nov 2027 to Feb 2028Quarter disclosed | risvutatug rezetecan (ris-rez) | GSK | Topline readout | Neoplasms, Lung | Scheduled | ClinicalTrials.gov |
| Nov 2027 to Feb 2028Quarter disclosed | velzatinib (IDRX-42) | GSK | Topline readout | Gastrointestinal Neoplasms | Scheduled | ClinicalTrials.gov |
| November 2027Month disclosed | risvutatug rezetecan (ris-rez) | GSK | Primary completion | Neoplasms, Lung | Scheduled | ClinicalTrials.gov |
| November 2027Month disclosed | GSK4532990 | GSK | Primary completion | Liver Diseases, Alcoholic | Scheduled | ClinicalTrials.gov |
| November 2027Month disclosed | velzatinib (IDRX-42) | GSK | Primary completion | Gastrointestinal Neoplasms | Scheduled | ClinicalTrials.gov |
| early 2028Half-year disclosed | DREAMM-10 | GSK | Interim readout | — | Scheduled | SEC Form 8-K |
| Jan to Apr 2028Quarter disclosed | depemokimab (GSK3511294) | GSK | Topline readout | Asthma | Scheduled | ClinicalTrials.gov |
| January 2028Month disclosed | depemokimab (GSK3511294) | GSK | Primary completion | Asthma | Scheduled | ClinicalTrials.gov |
| Feb to May 2028Quarter disclosed | mocertatug rezetecan | GSK | Topline readout | Neoplasms, Endometrial | Scheduled | ClinicalTrials.gov |
| Feb to May 2028Quarter disclosed | mmrvns | GSK | Topline readout | Measles; Measles-Mumps-Rubella+Chickenpox Vaccine | Scheduled | ClinicalTrials.gov |
| February 2028Month disclosed | mmrvns | GSK | Primary completion | Measles; Measles-Mumps-Rubella+Chickenpox Vaccine | Scheduled | ClinicalTrials.gov |
| February 2028Month disclosed | mocertatug rezetecan | GSK | Primary completion | Neoplasms, Endometrial | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | efimosfermin alfa | GSK | Topline readout | Non-alcoholic Fatty Liver Disease | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | efimosfermin alfa | GSK | Topline readout | Non-alcoholic Fatty Liver Disease | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | efimosfermin alfa | GSK | Primary completion | Non-alcoholic Fatty Liver Disease | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | efimosfermin alfa | GSK | Primary completion | Non-alcoholic Fatty Liver Disease | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2028Quarter disclosed | low dose of ints-tcv | GSK | Topline readout | Salmonella Infections | Scheduled | ClinicalTrials.gov |
| April 2028Month disclosed | low dose of ints-tcv | GSK | Primary completion | Salmonella Infections | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | velzatinib - subject to usan approval (IDRX-42) | GSK | Topline readout | Gastrointestinal Neoplasms | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | velzatinib - subject to usan approval (IDRX-42) | GSK | Primary completion | Gastrointestinal Neoplasms | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | Jemperli (dostarlimab) | GSK | Topline readout | Neoplasms, Head and Neck | Scheduled | SEC 8-K Exhibit 99.1 |
| Jun to Sep 2028Quarter disclosed | mmrvns vaccine | GSK | Topline readout | Measles; Mumps; Rubella | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | mrna seasonal flu vaccine | GSK | Topline readout | Influenza, Human | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | mrna seasonal flu vaccine | GSK | Primary completion | Influenza, Human | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | mmrvns vaccine | GSK | Primary completion | Measles; Mumps; Rubella | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | Jemperli (dostarlimab) | GSK | Primary completion | Neoplasms, Head and Neck | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | efimosfermin (BOS-580) | GSK | Topline readout | Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | efimosfermin (BOS-580) | GSK | Primary completion | Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2028Quarter disclosed | efimosfermin alfa | GSK | Topline readout | Liver Diseases, Alcoholic | Scheduled | ClinicalTrials.gov |
| August 2028Month disclosed | efimosfermin alfa | GSK | Primary completion | Liver Diseases, Alcoholic | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | GSK4527226 | GSK | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | GSK4527226 | GSK | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | altsonflex1-2-3 dose a | GSK | Topline readout | Diarrhoea | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | linerixibat (GSK2330672) | GSK | Topline readout | Pruritus | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | altsonflex1-2-3 dose a | GSK | Primary completion | Diarrhoea | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | linerixibat (GSK2330672) | GSK | Primary completion | Pruritus | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | depemokimab (GSK3511294) | GSK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | depemokimab (GSK3511294) | GSK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | OJJAARA (momelotinib) | GSK | Topline readout | VEXAS Syndrome | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | OJJAARA (momelotinib) | GSK | Primary completion | VEXAS Syndrome | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | depemokimab (GSK3511294) | GSK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | depemokimab (GSK3511294) | GSK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | HIBSAGO (bepirovirsen) | GSK | Topline readout | Hepatitis B | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | HIBSAGO (bepirovirsen) | GSK | Primary completion | Hepatitis B | Scheduled | ClinicalTrials.gov |
| Feb to May 2029Quarter disclosed | belantamab mafodotin | GSK | Topline readout | Multiple Myeloma | Scheduled | ClinicalTrials.gov |
| Feb to May 2029Quarter disclosed | GSK5784283 | GSK | Topline readout | Asthma | Scheduled | ClinicalTrials.gov |
| February 2029Month disclosed | GSK5784283 | GSK | Primary completion | Asthma | Scheduled | ClinicalTrials.gov |
| February 2029Month disclosed | belantamab mafodotin | GSK | Primary completion | Multiple Myeloma | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | Jemperli (dostarlimab) | GSK | Topline readout | Colonic Neoplasms; Neoplasms, Colon | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | cab la | GSK | Topline readout | HIV Infections | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | GSK5784283 | GSK | Topline readout | Nasal Polyps | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | GSK5784283 | GSK | Topline readout | Nasal Polyps | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | GSK3862995B | GSK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | GSK5784283 | GSK | Primary completion | Nasal Polyps | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | GSK5784283 | GSK | Primary completion | Nasal Polyps | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | cab la | GSK | Primary completion | HIV Infections | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | GSK3862995B | GSK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | Jemperli (dostarlimab) | GSK | Primary completion | Colonic Neoplasms; Neoplasms, Colon | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | depemokimab (GSK3511294) | GSK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | depemokimab (GSK3511294) | GSK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | adjuvanted rzv vaccine | GSK | Topline readout | Cardiovascular Disease | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | GSK5784283 | GSK | Topline readout | Asthma | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | adjuvanted rzv vaccine | GSK | Primary completion | Cardiovascular Disease | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | GSK5784283 | GSK | Primary completion | Asthma | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | mocertatug rezetecan | GSK | Topline readout | Neoplasms, Endometrial | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | GSK5784283 | GSK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | GSK5784283 | GSK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | GSK5784283 | GSK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | GSK5784283 | GSK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | mocertatug rezetecan | GSK | Primary completion | Neoplasms, Endometrial | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | Benlysta (belimumab) | GSK | Topline readout | Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | Benlysta (belimumab) | GSK | Topline readout | Lung Diseases, Interstitial | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | cab ula | GSK | Topline readout | HIV | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | cab ula | GSK | Primary completion | HIV | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | Benlysta (belimumab) | GSK | Primary completion | Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | Benlysta (belimumab) | GSK | Primary completion | Lung Diseases, Interstitial | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2029Quarter disclosed | mocertatug rezetecan | GSK | Topline readout | Ovarian Neoplasms | Scheduled | ClinicalTrials.gov |
| September 2029Month disclosed | mocertatug rezetecan | GSK | Primary completion | Ovarian Neoplasms | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | risvutatug rezetecan (ris-rez) | GSK | Topline readout | Neoplasms, Prostate | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | risvutatug rezetecan (ris-rez) | GSK | Primary completion | Neoplasms, Prostate | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | Jemperli (dostarlimab) | GSK | Topline readout | Neoplasms, Endometrial | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | Jemperli (dostarlimab) | GSK | Topline readout | Neoplasms, Rectal | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | Jemperli (dostarlimab) | GSK | Primary completion | Neoplasms, Rectal | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | Jemperli (dostarlimab) | GSK | Primary completion | Neoplasms, Endometrial | Scheduled | ClinicalTrials.gov |
| May to Aug 2030Quarter disclosed | mocertatug rezetecan (mo-rez) | GSK | Topline readout | Ovarian Neoplasms | Scheduled | ClinicalTrials.gov |
| May 2030Month disclosed | mocertatug rezetecan (mo-rez) | GSK | Primary completion | Ovarian Neoplasms | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2030Quarter disclosed | mocertatug rezetecan | GSK | Topline readout | Ovarian Neoplasms | Scheduled | ClinicalTrials.gov |